glp-faq
All news
Newssemaglutidestep-up-trialnovo-nordisk

STEP UP: Semaglutide 7.2 mg Hits 20.7% Weight Loss

STEP UP sub-analyses at ECO 2026 show semaglutide 7.2 mg achieving 20.7% weight loss — 27.7% in early responders. FDA approved the dose in March 2026.

May 20, 2026 · 4 min read

White pill case sitting on a table
Photo by Paul Zoetemeijer on Unsplash

Sub-analyses of the STEP UP trial, presented at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), show that semaglutide 7.2 mg weekly achieves 20.7% mean body weight loss at 72 weeks — roughly 6 percentage points higher than the established 2.4 mg dose. Among early responders, weight loss reached 27.7% at trial completion.

The Numbers

The STEP UP trial, published in The Lancet Diabetes & Endocrinology (lead author: Sean Wharton) and presented at ECO 2026, compared semaglutide 7.2 mg against both semaglutide 2.4 mg and placebo in 1,407 adults with obesity without type 2 diabetes (1,005 randomized to 7.2 mg, 201 to 2.4 mg, 201 to placebo).

Primary results at 72 weeks:

  • Semaglutide 7.2 mg: 20.7% mean body weight reduction
  • Semaglutide 2.4 mg: approximately 15% (consistent with STEP-1 data)
  • Placebo: approximately 3%

ECO 2026 sub-analysis — early responders: Among participants who lost at least 15% of body weight by week 24, mean weight loss at 72 weeks reached 27.7%. This early-response threshold identifies a subgroup where the higher dose appears to produce substantially greater long-term benefit.

Body composition data: 84% of total weight lost was fat mass, and abdominal fat decreased by approximately 30%. Lean mass preservation was broadly consistent with the body composition profile seen in SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide 2.4 mg) substudies.

Background and FDA Approval

The FDA approved semaglutide 7.2 mg in March 2026 under the Commissioner's National Priority Voucher program — an expedited pathway for clinically significant therapeutics. This is the highest approved weekly dose of semaglutide, and it's currently available as a weight management option in the US.

The higher dose follows a dose-escalation schedule more gradual than the 2.4 mg titration, reflecting the need to manage GI tolerability at a substantially higher drug concentration. The trial design matched the clinical reality: serious adverse events occurred in 6.8% of the 7.2 mg arm, 10.9% of the 2.4 mg arm, and 5.5% of the placebo arm.

That safety profile — where the 7.2 mg arm had fewer serious adverse events than the 2.4 mg arm — is an unusual finding and may reflect the different patient subpopulations that completed the longer titration required for 7.2 mg. Patients who are less tolerant of semaglutide's GI effects are more likely to discontinue before reaching 7.2 mg, leaving a more tolerant population at the higher dose.

Why It Matters

The 20.7% weight loss figure for semaglutide 7.2 mg narrows the efficacy gap with tirzepatide at 15 mg (approximately 20.9% in SURMOUNT-1 at 72 weeks), which has historically been the benchmark for maximum single-drug GLP-1 efficacy in the obesity-without-diabetes indication.

Clinically, this creates a new option for patients who:

  • Have responded well to semaglutide at lower doses but haven't reached weight-loss goals
  • Prefer to maximize semaglutide rather than switching to tirzepatide
  • Are already at 2.4 mg and are good candidates for uptitration to 7.2 mg

The semaglutide dosing schedule page covers the standard titration through 2.4 mg; updated dosing guidance for 7.2 mg will depend on how Novo Nordisk structures the uptitration protocol.

What to Watch

Real-world uptitration rates: Whether clinicians and patients actually use the 7.2 mg option — rather than defaulting to the established 2.4 mg ceiling — will determine the drug's practical impact. Insurance coverage for the 7.2 mg dose is not yet universal, and prior authorization requirements may vary by insurer.

The STEP UP T2D trial: A parallel STEP UP trial in adults with type 2 diabetes was published simultaneously in the same Lancet issue. The 7.2 mg dose produced clinically meaningful HbA1c reductions alongside substantial weight loss in that population, expanding the higher-dose option's relevance beyond weight management alone.

Competition: Semaglutide 7.2 mg's 20.7% result enters a market where retatrutide's Phase 2 data (24.2% at 48 weeks at 24 mg) is still the headline efficacy number on the horizon. If TRIUMPH Phase 3 results replicate, semaglutide 7.2 mg would sit between the two drugs in terms of expected weight loss outcomes — which is still a materially better option than the 2.4 mg ceiling many current patients are at.

Sources

Sources